TapewireFind a company

person · Reporting owner

Haddadin Yezan Munther

Disclosed activity across 1 company

Tapewire entity
41619
SEC CIK
0001718004

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Outlook Therapeutics, Inc.OTLK · Entity 608DirectorJune 02, 2026June 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Outlook Therapeutics, Inc.

Report date June 02, 2026 · Filed June 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect66,167 Reported balance After 2026-06-02 transaction · row 1
1 source row

Row 1 · 2026-06-02 · Purchase · Acquired 29,000 · Balance 66,167

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 02, 2026 Filed Jun 3, 2026 22:03 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 29,000 $0.83 $24,145.40
Disclosure

SEC source: 0001649989-26-000005 · primary_doc.xml · nonDerivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,167

Read SEC document
May 26, 2026 Filed May 27, 2026 19:24 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 34,000 $0.44 $14,960.00
Disclosure

SEC source: 0001649989-26-000003 · primary_doc.xml · nonDerivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,167

Read SEC document
October 03, 2025 Filed Oct 3, 2025 23:20 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 95,969 $0.00 Strike: $1.06 $0.00
Disclosure

SEC source: 0001649989-25-000006 · primary_doc.xml · derivative · entry 2

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,969

Underlying: Common Stock · 95,969 shares

Expires 2035-10-03

F2 · derivative.exercise_date: The options were granted under the 2024 Plan in lieu of $90,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
October 01, 2025 Filed Oct 3, 2025 23:20 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 286,734 $0.00 Strike: $1.04 $0.00
Disclosure

SEC source: 0001649989-25-000006 · primary_doc.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 286,734

Underlying: Common Stock · 286,734 shares

Expires 2035-10-01

F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
October 03, 2024 Filed Oct 4, 2024 00:30 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 19,771 $0.00 Strike: $5.25 $0.00
Disclosure

SEC source: 0001415889-24-024704 · form4-10032024_081007.xml · derivative · entry 3

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,771

Underlying: Common Stock · 19,771 shares

Expires 2034-10-03

F3 · derivative.exercise_date: The options were granted under the 2024 Plan in lieu of $90,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
October 01, 2024 Filed Oct 4, 2024 00:30 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 132,293 $0.00 Strike: $5.22 $0.00
Disclosure

SEC source: 0001415889-24-024704 · form4-10032024_081007.xml · derivative · entry 2

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,293

Underlying: Common Stock · 132,293 shares

Expires 2034-10-01

F2 · derivative.exercise_date: This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
October 01, 2024 Filed Oct 4, 2024 00:30 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 56,636 $0.00 Strike: $5.22 $0.00
Disclosure

SEC source: 0001415889-24-024704 · form4-10032024_081007.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,636

Underlying: Common Stock · 56,636 shares

Expires 2034-10-01

F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
March 28, 2024 Filed Mar 29, 2024 14:39 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 1,881.7112 $11.82 $22,241.83
Disclosure

SEC source: 0001415889-24-009394 · form4-03292024_020304.xml · nonDerivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,048.7112

F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $11.78 to $11.8249 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · balance_after: Reflects the Issuer's 1-for-20 reverse stock split effected on March 13, 2024.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 21:11 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 94,441 $0.00 Strike: $0.41 $0.00
Disclosure

SEC source: 0001415889-24-007332 · form4-03082024_090358.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,441

Underlying: Common Stock · 94,441 shares

Expires 2034-03-07

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
October 04, 2023 Filed Oct 5, 2023 21:07 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 358,337 $0.00 Strike: $0.24 $0.00
Disclosure

SEC source: 0001209191-23-052235 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 358,337

Underlying: Common Stock · 358,337 shares

Expires 2033-10-04

F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $75,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
March 29, 2023 Filed Mar 31, 2023 21:50 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 41,065 $0.00 Strike: $1.05 $0.00
Disclosure

SEC source: 0001209191-23-021913 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,065

Underlying: Common Stock · 41,065 shares

Expires 2033-03-29

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
October 07, 2022 Filed Oct 11, 2022 21:05 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 3,600 $1.27 $4,572.00
Disclosure

SEC source: 0001209191-22-053354 · doc4.xml · nonDerivative · entry 2

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,343

Read SEC document
October 06, 2022 Filed Oct 11, 2022 21:05 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 29,743 $1.29 $38,368.47
Disclosure

SEC source: 0001209191-22-053354 · doc4.xml · nonDerivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,743

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.279 - $1.2915, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 05, 2022 Filed Oct 7, 2022 20:39 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 71,998 $0.00 Strike: $1.25 $0.00
Disclosure

SEC source: 0001209191-22-053123 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,998

Underlying: Common Stock · 71,998 shares

Expires 2032-10-05

F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $75,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2023, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
March 23, 2022 Filed Mar 24, 2022 21:39 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 21,878 $0.00 Strike: $1.92 $0.00
Disclosure

SEC source: 0001209191-22-020952 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,878

Underlying: Common Stock · 21,878 shares

Expires 2032-03-23

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 23,2023; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Read SEC document
December 02, 2021 Filed Dec 2, 2021 22:09 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 10,000 $1.39 $13,900.00
Disclosure

SEC source: 0001209191-21-067650 · doc4.xml · nonDerivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.385 - $1.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
October 05, 2021 Filed Oct 7, 2021 21:06 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 47,335 $0.00 Strike: $2.12 $0.00
Disclosure

SEC source: 0001209191-21-059950 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,335

Underlying: Common Stock · 47,335 shares

Expires 2031-10-05

F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $82,500 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
April 19, 2021 Filed Apr 20, 2021 23:56 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 10,000 $1.82 $18,200.00
Disclosure

SEC source: 0001209191-21-027685 · doc4.xml · nonDerivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Read SEC document
March 24, 2021 Filed Mar 26, 2021 22:08 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 20,873 $0.00 Strike: $2.27 $0.00
Disclosure

SEC source: 0001209191-21-023283 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,873

Underlying: Common Stock · 20,873 shares

Expires 2031-03-24

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
October 05, 2020 Filed Oct 5, 2020 22:47 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 160,474 $0.51 Strike: $0.71 $82,499.68
Disclosure

SEC source: 0001209191-20-053873 · doc4.xml · derivative · entry 2

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,474

Underlying: Common Stock · 160,474 shares

Expires 2030-10-05

F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $82,500 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 22:47 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 290,372 $0.00 Strike: $0.71 $0.00
Disclosure

SEC source: 0001209191-20-053873 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 290,372

Underlying: Common Stock · 290,372 shares

Expires 2030-10-01

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
September 22, 2020 Filed Sep 22, 2020 21:14 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 PurchaseCommon Stock 10,000 $0.72 $7,245.00
Disclosure

SEC source: 0001209191-20-051507 · doc4.xml · nonDerivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Read SEC document
July 17, 2020 Filed Jul 21, 2020 22:06 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 135,000 $0.00 Strike: $1.58 $0.00
Disclosure

SEC source: 0001209191-20-043218 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2030-07-17

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
March 19, 2020 Filed Mar 20, 2020 21:52 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $0.54 $0.00
Disclosure

SEC source: 0001209191-20-020509 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-03-19

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Read SEC document
January 02, 2020 Filed Jan 7, 2020 01:29 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 5,980 $0.99 Strike: $0.88 $5,892.09
Disclosure

SEC source: 0001209191-20-002167 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,980

Underlying: Common Stock · 5,980 shares

Expires 2030-01-02

F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $5,892.86 cash fees payable under the Issuers's non-employee Director compensation program and vest in three equal quarterly installments on the last day of each remaining fiscal quarter (3/31, 6/30 and 9/30) such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
October 03, 2019 Filed Oct 7, 2019 22:11 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 80,176 $0.99 Strike: $1.40 $78,997.41
Disclosure

SEC source: 0001209191-19-052712 · doc4.xml · derivative · entry 2

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,176

Underlying: Common Stock · 80,176 shares

Expires 2029-10-03

F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $79,000 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
October 03, 2019 Filed Oct 7, 2019 22:11 UTC Outlook Therapeutics, Inc. OTLK · Entity 608 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $1.40 $0.00
Disclosure

SEC source: 0001209191-19-052712 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-10-03

F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Read SEC document
October 31, 2017 Filed Nov 2, 2017 22:13 UTC Outlook Therapeutics, Inc. ONS · Entity 608 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $1.26 $0.00
Disclosure

SEC source: 0001209191-17-058966 · doc4.xml · derivative · entry 1

Haddadin Yezan Munther · CIK 0001718004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2027-10-31

F1 · derivative.exercise_date: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on October 31, 2020, subject to the Reporting Person providing continued service through such date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.